A 5.7-year prospective study of 1380 patients treated for psoriasis with oral methoxsalen (8-methoxypsoralen) and ultraviolet A photochemotherapy (PUVA) revealed that after adjustment for exposures to ionizing radiation and topical tar preparations, the risk that cutaneous squamous-cell carcinoma would develop at least 22 months after the first exposure to PUVA was 12.8 times higher in patients exposed to a high dose than in those exposed to a low dose (95 per cent confidence interval, 5.8 to 28.5). No substantial dose-related increase was noted for basal-cell carcinoma. The dose-dependent risk of cutaneous squamous-cell carcinoma suggests that PUVA can act as an independent carcinogen. In our study, morbidity associated with these tumors has been limited, but further follow-up is needed. Meanwhile, patients treated with PUVA should be followed closely for the possible development of cutaneous squamous-cell carcinoma.
This article has been cited by other articles:
Nijsten, T., Looman, C. W. N., Stern, R. S.
(2007). Clinical Severity of Psoriasis in Last 20 Years of PUVA Study. Arch Dermatol
143: 1113-1121
[Abstract][Full Text]
Gelfand, J. M.
(2007). Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go. Arch Dermatol
143: 1191-1193
[Full Text]
Stern, R. S.
(2007). Psoralen and Ultraviolet A Light Therapy for Psoriasis. NEJM
357: 682-690
[Full Text]
Stern, R. S.
(2006). Lymphoma Risk in Psoriasis: Results of the PUVA Follow-up Study.. Arch Dermatol
142: 1132-1135
[Abstract][Full Text]
Parrish, J. A.
(2005). Immunosuppression, Skin Cancer, and Ultraviolet A Radiation. NEJM
353: 2712-2713
[Full Text]
Lambertini, L., Surin, K., Ton, T.-V. T., Clayton, N., Dunnick, J. K., Kim, Y., Hong, H.-H. L., Devereux, T. R., Sills, R. C.
(2005). Analysis of p53 Tumor Suppressor Gene, H-ras Protooncogene and Proliferating Cell Nuclear Antigen (PCNA) in Squamous Cell Carcinomas of HRA/Skh Mice Following Exposure to 8-Methoxypsoralen (8-MOP) and UVA Radiation (PUVA Therapy). Toxicol Pathol
33: 292-299
[Abstract][Full Text]
Oh, D. H., King, B. A., Boxer, S. G., Hanawalt, P. C.
(2001). Spatially localized generation of nucleotide sequence-specific DNA damage. Proc. Natl. Acad. Sci. USA
98: 11271-11276
[Abstract][Full Text]
Alam, M., Ratner, D.
(2001). Cutaneous Squamous-Cell Carcinoma. NEJM
344: 975-983
[Full Text]
Kawamura, A. Jr, Sekine, T., Sekiguchi, M., Yanoma, S., Kaneko, A., Haneda, T., Moriya, Y., Hayasaka, K.-i., Kakizoe, T.
(2000). Six-year Disease-free Survival of a Patient with Metastatic Eyelid Squamous Cell Carcinoma and Colon Adenocarcinoma after Repeated Postoperative Adoptive Immunotherapy. Jpn J Clin Oncol
30: 267-271
[Abstract][Full Text]
Monti, P., Inga, A., Aprile, A., Campomenosi, P., Menichini, P., Ottaggio, L., Viaggi, S., Ghigliotti, G., Abbondandolo, A., Fronza, G.
(2000). p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis
15: 127-132
[Abstract][Full Text]
Stern, R. S., Lunder, E. J.
(1998). Risk of Squamous Cell Carcinoma and Methoxsalen (Psoralen) and UV-A Radiation (PUVA): A Meta-analysis. Arch Dermatol
134: 1582-1585
[Abstract][Full Text]
Morison, W. L., Baughman, R. D., Day, R. M., Forbes, P. D., Hoenigsmann, H., Krueger, G. G., Lebwohl, M., Lew, R., Naldi, L., Parrish, J. A., Piepkorn, M., Stern, R. S., Weinstein, G. D., Whitmore, S. E.
(1998). Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy. Arch Dermatol
134: 595-598
[Abstract][Full Text]
Stern, R. S., Nichols, K. T., Vakeva, L. H., The PUVA Follow-up Study,
(1997). Malignant Melanoma in Patients Treated for Psoriasis with Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA). NEJM
336: 1041-1045
[Abstract][Full Text]
Wolff, K.
(1997). Should PUVA Be Abandoned?. NEJM
336: 1090-1091
[Full Text]
McHenry, P M, Williams, H C, Bingham, E A
(1995). Fortnightly Review: Management of atopic eczema. BMJ
310: 843-847
[Abstract][Full Text]
Greaves, M. W., Weinstein, G. D.
(1995). Treatment of Psoriasis. NEJM
332: 581-589
[Full Text]
Previous
